기본 정보
- 표준 SMILES
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.Cl- InChIKey
OWNWYCOLFIFTLK-YDALLXLXSA-N- 분자식
- C13H22ClNO3
- 평균 분자량
- 275.77 g/mol
- 단동위원소 질량
- 275.12882124
개요
Levalbuterol Hydrochloride is the hydrochloride salt form of levalbuterol, a relatively selective sympathomimetic beta-2 adrenergic receptor agonist with bronchodilator activity. Levalbuterol hydrochloride binds to beta-2 adrenergic receptors in bronchial smooth muscle and activates intracellular adenyl cyclase, thereby increasing the production of cyclic-3', 5'-adenosine monophosphate (cAMP). Increased cAMP levels lead to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation of bronchial smooth muscles. The increased cyclic AMP concentrations also inhibit the release of inflammatory mediators from mast cells.
이름 및 식별자
- 우선 이름
- Levalbuterol Hydrochloride
- IUPAC
- 4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;hydrochloride
이름 및 동의어
이름 더 보기
데이터베이스 식별자
- CAS
50293-90-8- PubChem CID
- 123601
- DTXSID
DTXSID20198296- ChEMBL
CHEMBL1201061- UNII
- WDQ1526QJM
- EC Number
- 627-135-3
물성
구조 계산 물성
- 극성 표면적
- 72.7 Ų
- 수소 결합 공여자 수
- 5
- 수소 결합 수용자 수
- 4
- 회전 가능 결합 수
- 5
- 무거운 원자 수
- 18
- 형식 전하
- 0
- 복잡도
- 227
실험 및 물리화학적 성질
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
안전 및 규제
GHS 분류
GHS Classification
Danger
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 43 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
유해성 정보
독성 정보
Toxicity Summary
Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.
화학 및 산업
약리 정보
Metabolism/Metabolites
Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours
FDA Pharmacological Classification
LEVALBUTEROL HYDROCHLORIDE
beta2-Adrenergic Agonist [EPC]; Adrenergic beta2-Agonists [MoA]
LEVALBUTEROL INHALATION SOLUTION
Adrenergic beta2-Agonists [MoA]; beta2-Adrenergic Agonist [EPC]
용도 및 제조
관련 반응
연결된 노트
불러오는 중…